- +1 518-300-1215 (US)
- sales@kdmarketinsights.jp
脆弱性X症候群（FXS）市場、2033年までに6,640万米ドルの売上を予測：KDMIのアナリストによる成長分析 市場は、治療タイプ、投与経路、患者の年齢層、エンドユーザー、地域別に区分されています。
According to a research report on the global Fragile X Syndrome (FXS) market , the market is projected to grow at a CAGR of 4.1 % between 2024 and 2033, and is further projected to generate a market size of USD 66.4 Million by the end of 2033. In 2024, the market size was USD 46.3 Million .
Fragile X Syndrome (FXS) is a genetic disorder caused by a mutation in the X chromosome. This harmful genetic change results in physical abnormalities, learning disabilities, cognitive impairments, developmental delays, behavioral problems, and many other health issues. Globally, millions of babies are born with serious genetic disorders every year. However, only 30% of people with rare genetic disorders receive proper and timely diagnosis. The increase in the prevalence of genetic disorders is mainly associated with lifestyle changes and environmental changes. Hence, as the rate of genetic disorders increases, the need for treatments, diagnostics, and medical research increases, leading to an expansion of the FXS market across the globe. Neuren Pharmaceuticals, Eli Lilly and Company, and Bellus Health Inc. are some of the key players in the global Fragile X Syndrome (FXS) market.
Fragile X Syndrome (FXS) is the most common genetic disorder that causes intellectual disability, affecting approximately 1 in 5,000 men and 1 in 8,000 women. The growth of the Fragile X Syndrome (FXS) market in Japan is attributed to advances in FXS treatment. However, the FXS market in Japan is growing due to increased government funding and the discovery of new drugs. Many leading companies are introducing groundbreaking treatments, increasing awareness and making them accessible to the general public. Tetra Therapeutics and GEXVal are some of the key parties in the Fragile X Syndrome (FXS) market in Japan.
Fragile X Syndrome ( FXS ) Market : Report Scope |
|
|
Base year |
2023 |
|
Estimated market size |
US$46.3 million in 2024 |
|
Estimated Year |
2024-2033 |
|
Estimated market size |
US$66.4 million in 2033 |
|
CAGR value |
4.1% |
|
Fragile X Syndrome ( FXS ) Market Key Trends/Key Growth Drivers |
|
|
Constraining factors |
|
|
Fragile X Syndrome ( FXS ) Market Segmentation |
|
|
Fragile X Syndrome ( FXS ) Market Key Players |
Anavex Life Sciences Corp., Ovid Therapeutics, Neuren Pharmaceuticals, Eli Lilly and Company, Bellus Health Inc., AMO Pharma, Marinus Pharmaceuticals Inc., Karus Therapeutics. SA, Zainerba Pharmaceuticals Inc., and Lupin Pharmaceuticals. |
Expanding genetic screening programs
Genetic screening refers to a public health program that targets specific asymptomatic populations to identify those at high risk and provide preventive care, early management, and reproductive planning. It is more than just a test. Rather, it is a detailed and structured effort that includes education and counseling of designated populations regarding the associated risks and benefits. Recommended genetic screening tests for Fragile X Syndrome (FXS) include exome sequencing, chromosomal microarray analysis, and DNA testing specific to FXS disorder. Therefore, the expansion of genetic screening programs will invigorate the FXS market by increasing the need for targeted treatments, funding for medical research, and healthcare breakthroughs. This will ultimately promote better patient care and improve the overall market dynamics.
Drug development-friendly policies
The process of drug development involves many experimental trials, extensive research, and approval processes. Currently, artificial intelligence (AI) is becoming more prevalent in drug development, with the FDA acknowledging its growing integration in the pharmaceutical industry and across various therapeutic areas. Furthermore, the Center for Drug Evolution and Research (CDER) reports a notable surge in drug approval applications featuring AI-based advancements in recent years. Therefore, favorable government policies for drug development, such as faster approvals, enhanced research funding, and other innovation incentives, are propelling the Fragile X Syndrome (FXS) market forward. Such efforts motivate pharmaceutical companies to invest in drug research, expand treatments, and optimize clinical procedures, ultimately improving patient outcomes and resulting in industry growth.
Limited patient numbers:
Fragile X Syndrome (FXS) is a rare genetic disease with a small number of patients, making it an unfavorable area for pharmaceutical companies to conduct large-scale drug research and production. Therefore, the small number of patients reduces the market potential, hindering pharmaceutical research and limiting the profitability of the FXS market.
Cost-intensive drug discovery:
The costly and lengthy path involved in drug discovery, regulatory approval and treatment of Fragile X Syndrome (FXS) severely impedes market development, slowing scientific research, discouraging biotechnology companies, delaying new therapies, limiting patient reach and ultimately stifling the overall FXS market and medical progress.
Experts at KD Market Insights have segmented the Global Fragile X Syndrome (FXS) Market research report into:
|
By treatment type |
|
|
By route of administration |
|
|
Patient age group |
|
|
By end user |
|
|
By region |
|
North America leads the fragile X syndrome (FXS) market, with strong research and development activities driving the market. Moreover, advanced healthcare system, extensive research into rare genetic disorders, growing public awareness, and favorable regulatory policies in Canada and the United States further drive the market in the region. The United States holds the largest share of the fragile X syndrome (FXS) market in the region over a period owing to the presence of pharmaceutical companies, increasing genetic testing, growing adoption of innovative therapies, and promising drug development pipeline. As per the findings, a total of 129,624 genetic tests have been registered in the genetic testing registry in the United States by November 2022.
Asia Pacific (APAC) is set to witness the fastest market growth during the forecast period. The region acts as a hub for pharmaceutical business. This is mainly due to the extensive distribution channels and trade relationships. In addition, the increasing use of generic drugs, economic growth, consumer demand, and evolving healthcare framework are also driving the market. India is also upgrading the fragile X syndrome (FXS) market due to its vast population, expanding genetic screening programs, growing public awareness, growing healthcare investments, and strengthening healthcare system. In addition, Japan's economic growth is likely to expand at a pace that exceeds its expected growth capacity. China is also a major contributor to this regional market. China is implementing one of the world's largest planned urban remodeling programs to promote healthcare development. Also, numerous biotechnology research and pharmaceutical developments support the overall healthcare framework and economic growth goals.
In Europe, government agencies such as the European Medicines Agency (EMA) are supporting early detection and preventive screening for Fragile X Syndrome (FXS), which is expected to drive the market expansion in the coming years. Moreover, the UK is at the forefront of market development in the region due to improved diagnostic methods and increasing strong healthcare policies. Several factors are driving the market development in this region, including rising incidence of genetic diseases, growing public awareness about genetic diseases, and greater availability of medical solutions.
Some of the key players with the top share in the global Fragile X Syndrome (FXS) market are:
1. Abstract
1.1. Market Overview
1.2. Main findings
1.3. Market Trends
1.4. Market Outlook
2. Introduction
2.1. Scope of the Report
2.2. Research methodology
2.3. Definitions and Prerequisites
2.4. Acronyms and Abbreviations
3. Market Dynamics
3.1. Drivers
3.2. Inhibitors
Opportunities
Challenges
4. Global Fragile X Syndrome (FXS) Market
4.1. Market Overview
4.2. Market size and forecast
4.3. Market segmentation
4.3.1. By treatment type
4.3.2. By route of administration
4.3.3. Patient age groups
4.3.4. By end user
4.3.5. By region
5. Market segmentation by treatment type
5.1.1. Pharmacological therapy
Psychotherapy
5.1.3. Education and Training
Other
6. Market segmentation by route of administration
Oral
6.1.2. Injectables
6.1.3. Topical medications
Other
7. Market segmentation by patient age group
Children
Adults
Elderly
Other
8. Market segmentation by end user
Hospitals
8.1.2. Specialized clinics
8.1.3. Home medical care
Other
9. Regional Analysis
North America
United States
9.1.1.1. Market size and forecast
9.1.1.2. Main trends and developments
9.1.1.3. Market analysis by therapy type, route of administration, patient age group and end user
Canada
9.1.2.1. Market size and forecast
9.1.2.2. Key trends and developments
9.1.2.3. Market analysis by therapy type, route of administration, patient age group and end user
Mexico
9.1.3.1. Market size and forecast
9.1.3.2. Key trends and developments
9.1.3.3. Market analysis by therapy type, route of administration, patient age group and end user
Europe
United Kingdom
9.2.1.1. Market size and forecast
9.2.1.2. Key trends and developments
9.2.1.3. Market analysis by therapy type, route of administration, patient age group and end user
Germany
9.2.2.1. Market size and forecast
9.2.2.2. Main trends and developments
9.2.2.3. Market analysis by therapy type, route of administration, patient age group and end user
France
9.2.3.1. Market size and forecast
9.2.3.2. Main trends and developments
9.2.3.3. Market analysis by therapy type, route of administration, patient age group and end user
Italy
9.2.4.1. Market size and forecast
9.2.4.2. Key trends and developments
9.2.4.3. Market analysis by therapy type, route of administration, patient age group and end user
Spain
9.2.5.1. Market size and forecast
9.2.5.2. Main trends and developments
9.2.5.3. Market analysis by therapy type, route of administration, patient age group and end user
9.2.6. Rest of Europe
9.2.6.1. Market size and forecast
9.2.6.2. Main trends and developments
9.2.6.3. Market analysis by therapy type, route of administration, patient age group and end user
9.3. Asia Pacific
China
9.3.1.1. Market size and forecast
9.3.1.2. Key trends and developments
9.3.1.3. Market analysis by therapy type, route of administration, patient age group and end user
Japan
9.3.2.1. Market size and forecast
9.3.2.2. Main trends and developments
9.3.2.3. Market analysis by therapy type, route of administration, patient age group and end user
India
9.3.3.1. Market size and forecast
9.3.3.2. Main trends and developments
9.3.3.3. Market analysis by therapy type, route of administration, patient age group and end user
Australia
9.3.4.1. Market size and forecast
9.3.4.2. Main trends and developments
9.3.4.3. Market analysis by therapy type, route of administration, patient age group and end user
South Korea
9.3.4.5. Market size and forecast
9.3.4.6. Key trends and developments
9.3.4.7. Market analysis by therapy type, route of administration, patient age group and end user
9.3.5. Rest of Asia Pacific
9.3.5.1. Market size and forecast
9.3.5.2. Main trends and developments
9.3.5.3. Market analysis by therapy type, route of administration, patient age group and end user
9.4. Latin America
Brazil
9.4.1.1. Market size and forecast
9.4.1.2. Key trends and developments
9.4.1.3. Market analysis by therapy type, route of administration, patient age group and end user
Argentina
9.4.2.1. Market size and forecast
9.4.2.2. Key trends and developments
9.4.2.3. Market analysis by therapy type, route of administration, patient age group and end user
Colombia
9.4.3.1. Market size and forecast
9.4.3.2. Key trends and developments
9.4.3.3. Market analysis by therapy type, route of administration, patient age group and end user
9.4.4. Rest of Latin America
9.4.4.1. Market size and forecast
9.4.4.2. Main trends and developments
9.4.4.3. Market analysis by therapy type, route of administration, patient age group and end user
9.5. Middle East and Africa
South Africa
9.5.1.1. Market size and forecast
9.5.1.2. Key trends and developments
9.5.1.3. Market analysis by therapy type, route of administration, patient age group and end user
Saudi Arabia
9.5.2.1. Market size and forecast
9.5.2.2. Main trends and developments
9.5.2.3. Market analysis by therapy type, route of administration, patient age group and end user
United Arab Emirates
9.5.3.1. Market size and forecast
9.5.3.2. Main trends and developments
9.5.3.3. Market analysis by therapy type, route of administration, patient age group and end user
9.5.4. Rest of the Middle East and Africa
9.5.4.1. Market size and forecast
9.5.4.2. Main trends and developments
9.5.4.3. Market analysis by therapy type, route of administration, patient age group and end user
10. Competitive Landscape
10.1. Market Share Analysis
10.2. Company Profile
10.3.Eli Lilly and Company
10.4. Bellus Health
10.5.AMO Pharma
10.6.Marinus Pharmaceuticals, Inc.
10.7. Callus Therapeutics SA
10.8. Zynerba Pharmaceuticals
10.9. Lupin Pharmaceuticals
11. Strategic Recommendations
12. Appendix
12.1. List of Tables
12.2. List of Figures and Tables
13. References
